CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

New technologies for intensive prevention programs after myocardial infarction: rationale and design of the NET-IPP trial Heart Regeneration by Endogenous Stem Cells and Cardiomyocyte Proliferation: Controversy, Fallacy, and Progress Chronic total occlusion intervention of the non-infarct-related artery in acute myocardial infarction patients: the Korean multicenter chronic total occlusion registry Coronary CT Angiography and 5-Year Risk of Myocardial Infarction Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial Risk Stratification Guided by the Index of Microcirculatory Resistance and Left Ventricular End-Diastolic Pressure in Acute Myocardial Infarction Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial

Clinical Trial2017 Apr 18;69(15):1913-1920.

JOURNAL:J Am Coll Cardiol. Article Link

Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction

Pöss J, Köster J, Fuernau G et al. Keywords: TIMI flow grade; acute coronary syndrome; mortality; percutaneous coronary intervention; prognosis; risk score; IABP-SHOCK II trial

FULL TEXT PDF